Alnylam Pharmaceuticals Inc (0HD2)

Profile

https://www.alnylam.com

Alnylam Pharmaceuticals Inc is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of therapeutics based on RNA interference technology. The company focuses on treating genetically defined and other hard-to-treat diseases by silencing specific genes implicated in disease pathways. Its commercial portfolio includes approved RNAi medicines for rare conditions such as hereditary transthyretin-mediated amyloidosis and primary hyperoxaluria type 1, alongside therapies targeting acute hepatic porphyria and other metabolic and cardiovascular disorders. Alnylam also maintains a broad clinical pipeline in cardiometabolic disease, neuroscience, and hematology, aiming to address areas of high unmet medical need with targeted RNAi-based approaches. The company works across the United States, Europe, and other international markets, supported by strategic collaborations with healthcare providers, commercial partners, and technology firms. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals today plays a central role in bringing RNAi therapeutics into routine medical practice and is widely regarded as a pioneer in this modality.